Global Postmenopausal Osteoporosis Treatment Industry Poised for Steady Growth at 3.5% CAGR, Reaching US$15.2 Billion by 2034 | FMI

 

 

The Global Postmenopausal Osteoporosis Treatment Industry is poised for steady growth, with a projected valuation of US$15,171.90 million by 2034. This translates to a Compound Annual Growth Rate (CAGR) of 3.50% anticipated between 2024 and 2034. In 2024, the market size is estimated to be US$9,863.6 million, highlighting the increasing demand for solutions to manage this prevalent condition.

The growing awareness about the diagnosis and treatment of postmenopausal osteoporosis is contributing to the expansion of the market. An increase in healthcare facilities such as trauma centers is also driving the growth of the postmenopausal osteoporosis treatment market. Increasing investments in research and development activities for the generation of drugs and growing awareness about osteoporosis are also adding to the growth of the postmenopausal osteoporosis treatment market.

Request our market overview sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-18362

Increasing healthcare spending, coupled with better insurance coverage, enhances access to postmenopausal osteoporosis treatments, making them more accessible to a larger population. Greater awareness campaigns among healthcare professionals and the public contribute to increased diagnosis rates and proactive management of osteoporosis. This leads to more individuals seeking and receiving treatment.

Increasing supportive government policies, subsidies, or healthcare initiatives to promote bone health and prevent osteoporosis can positively impact treatment access and affordability, driving the market demand. Increasing research into bone health, the underlying causes of postmenopausal osteoporosis, and developing new drugs or therapies drive innovation and expand treatment options are expected to fuel the market demand during the forecast period.

Global Postmenopausal Osteoporosis Treatment Industry Key Takeaways

• From 2019 to 2023, the postmenopausal osteoporosis treatment market was valued at a CAGR of 4.40%
• Based on drug class, the bisphosphonate segment is expected to account for a share of 42% in 2024.
• Global postmenopausal osteoporosis treatment demand in China is predicted to account for a CAGR of 5.9% in 2024.
• In the United States, the postmenopausal osteoporosis treatment industry is expected to account for a CAGR of 2.1% in 2024.
• Germany is projected to expand by a value CAGR of 3.0% between 2023 and 2034.
• The postmenopausal osteoporosis treatment market in Japan is anticipated to record a CAGR of 2.2% in 2024.

“The increasing global aging population and growing demand for effective treatments to prevent fractures and maintain bone health are anticipated to drive the market growth during the forecast period,” – says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)

Purchase to Uncover Segment-specific Information, Identify Key Trends, Drivers, and Challenges:
https://www.futuremarketinsights.com/checkout/18362

Global Postmenopausal Osteoporosis Treatment Industry Competitive Landscape

The postmenopausal osteoporosis treatment market is consolidated in nature since a large number of dominant key players are present across the world. To attain a dominant position, the companies may follow an inorganic growth strategy such as merger, expansion, acquisition, partnership, and collaboration of the companies along with a new product development strategy.

Postmenopausal osteoporosis treatment manufacturers have expanded their market presence globally, targeting emerging markets with growing populations and increasing disposable income. This expansion has opened up new opportunities for market growth.

• Radius health developed abaloparatide (Tymlos), an anabolic agent for the treatment of osteoporosis.
• UCB – manufacturers of bazedoxifene, combined with conjugated estrogens (Duavee), used to treat osteoporosis in postmenopausal women.
• GSK (GlaxoSmithKline) – manufactured raloxifene (Evista), a selective estrogen receptor modulator used in osteoporosis treatment.
• Teva Pharmaceutical Industries Ltd. Producer of generic versions of various osteoporosis medications, contributing to treatment accessibility.

Global Postmenopausal Osteoporosis Treatment Industry Key Players:

• Amgen Inc.
• Eli Lilly and Company
• Novartis International AG
• Gilead Sciences Inc.
• Teva Pharmaceutical Industries Ltd.
• Merck & Co. Inc.
• Pfizer Inc.
• GlaxoSmithKline plc
• Roche Holding AG
• Johnson & Johnson
• Sanofi S.A.
• Actavis Pharma, Inc. (now part of Teva Pharmaceuticals)
• Sun Pharmaceutical Industries Ltd.
• Mylan N.V. (now part of Viatris Inc.)
• Accord Healthcare Limited

Global Postmenopausal Osteoporosis Treatment Industry Segments Covered in the Report

By Drug Type:

• Bisphosphonates
• Vitamin D3
• Estrogen Agonist/Antagonist
• Hormone Replacement Therapy
• Parathyroid Hormone Therapy
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

  By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia and Pacific
• The Middle East and Africa

Authored by:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer, Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube